|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAF1 |
Gene summary for FAF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAF1 | Gene ID | 11124 |
| Gene name | Fas associated factor 1 | |
| Gene Alias | CGI-03 | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9UNN5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11124 | FAF1 | CCI_1 | Human | Cervix | CC | 9.08e-31 | 2.03e+00 | 0.528 |
| 11124 | FAF1 | CCI_2 | Human | Cervix | CC | 2.28e-16 | 1.80e+00 | 0.5249 |
| 11124 | FAF1 | CCI_3 | Human | Cervix | CC | 1.73e-33 | 2.07e+00 | 0.516 |
| 11124 | FAF1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.35e-22 | -5.96e-01 | 0.0155 |
| 11124 | FAF1 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.18e-11 | 6.24e-01 | -0.1954 |
| 11124 | FAF1 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.60e-04 | 3.55e-01 | -0.2602 |
| 11124 | FAF1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 9.84e-03 | -4.90e-01 | -0.1207 |
| 11124 | FAF1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.90e-07 | -6.73e-01 | -0.2061 |
| 11124 | FAF1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 4.50e-03 | -4.75e-01 | -0.1462 |
| 11124 | FAF1 | HTA11_9341_2000001011 | Human | Colorectum | SER | 2.79e-02 | -3.36e-01 | -0.00410000000000005 |
| 11124 | FAF1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.01e-05 | -5.15e-01 | -0.0179 |
| 11124 | FAF1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.14e-18 | -5.55e-01 | 0.096 |
| 11124 | FAF1 | HTA11_9408_2000001011 | Human | Colorectum | AD | 7.06e-03 | -6.34e-01 | 0.0451 |
| 11124 | FAF1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.76e-08 | -4.00e-01 | 0.294 |
| 11124 | FAF1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 6.38e-05 | 6.66e-01 | 0.3487 |
| 11124 | FAF1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.52e-04 | -6.45e-01 | 0.2585 |
| 11124 | FAF1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.94e-13 | -5.29e-01 | 0.3005 |
| 11124 | FAF1 | F007 | Human | Colorectum | FAP | 3.06e-02 | -2.96e-01 | 0.1176 |
| 11124 | FAF1 | A001-C-207 | Human | Colorectum | FAP | 4.00e-06 | -3.96e-01 | 0.1278 |
| 11124 | FAF1 | A015-C-203 | Human | Colorectum | FAP | 2.95e-37 | -6.66e-01 | -0.1294 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00432541 | Colorectum | SER | regulation of protein-containing complex assembly | 119/2897 | 428/18723 | 3.34e-11 | 5.86e-09 | 119 |
| GO:00098961 | Colorectum | SER | positive regulation of catabolic process | 132/2897 | 492/18723 | 4.16e-11 | 6.72e-09 | 132 |
| GO:19033641 | Colorectum | SER | positive regulation of cellular protein catabolic process | 56/2897 | 155/18723 | 2.09e-10 | 2.85e-08 | 56 |
| GO:20012331 | Colorectum | SER | regulation of apoptotic signaling pathway | 101/2897 | 356/18723 | 3.05e-10 | 4.07e-08 | 101 |
| GO:00313311 | Colorectum | SER | positive regulation of cellular catabolic process | 114/2897 | 427/18723 | 1.22e-09 | 1.27e-07 | 114 |
| GO:00313341 | Colorectum | SER | positive regulation of protein-containing complex assembly | 73/2897 | 237/18723 | 1.89e-09 | 1.84e-07 | 73 |
| GO:00431611 | Colorectum | SER | proteasome-mediated ubiquitin-dependent protein catabolic process | 105/2897 | 412/18723 | 7.48e-08 | 4.70e-06 | 105 |
| GO:00971911 | Colorectum | SER | extrinsic apoptotic signaling pathway | 58/2897 | 219/18723 | 1.76e-05 | 5.22e-04 | 58 |
| GO:20012351 | Colorectum | SER | positive regulation of apoptotic signaling pathway | 36/2897 | 126/18723 | 1.29e-04 | 2.63e-03 | 36 |
| GO:2001236 | Colorectum | SER | regulation of extrinsic apoptotic signaling pathway | 39/2897 | 151/18723 | 6.67e-04 | 8.94e-03 | 39 |
| GO:00451851 | Colorectum | SER | maintenance of protein location | 26/2897 | 94/18723 | 1.76e-03 | 1.81e-02 | 26 |
| GO:00421762 | Colorectum | MSS | regulation of protein catabolic process | 145/3467 | 391/18723 | 2.03e-18 | 1.17e-15 | 145 |
| GO:00098962 | Colorectum | MSS | positive regulation of catabolic process | 163/3467 | 492/18723 | 3.10e-15 | 9.22e-13 | 163 |
| GO:19033622 | Colorectum | MSS | regulation of cellular protein catabolic process | 99/3467 | 255/18723 | 1.90e-14 | 5.37e-12 | 99 |
| GO:00104982 | Colorectum | MSS | proteasomal protein catabolic process | 157/3467 | 490/18723 | 2.39e-13 | 5.25e-11 | 157 |
| GO:00313312 | Colorectum | MSS | positive regulation of cellular catabolic process | 140/3467 | 427/18723 | 7.02e-13 | 1.33e-10 | 140 |
| GO:00457322 | Colorectum | MSS | positive regulation of protein catabolic process | 85/3467 | 231/18723 | 3.66e-11 | 4.57e-09 | 85 |
| GO:20012332 | Colorectum | MSS | regulation of apoptotic signaling pathway | 116/3467 | 356/18723 | 1.02e-10 | 1.06e-08 | 116 |
| GO:00431612 | Colorectum | MSS | proteasome-mediated ubiquitin-dependent protein catabolic process | 127/3467 | 412/18723 | 7.70e-10 | 6.32e-08 | 127 |
| GO:00432542 | Colorectum | MSS | regulation of protein-containing complex assembly | 130/3467 | 428/18723 | 1.38e-09 | 1.03e-07 | 130 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAF1 | SNV | Missense_Mutation | c.1948G>C | p.Glu650Gln | p.E650Q | Q9UNN5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.954) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAF1 | SNV | Missense_Mutation | novel | c.164A>C | p.Glu55Ala | p.E55A | Q9UNN5 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAF1 | SNV | Missense_Mutation | c.1639N>C | p.Glu547Gln | p.E547Q | Q9UNN5 | protein_coding | tolerated(0.14) | probably_damaging(0.996) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAF1 | SNV | Missense_Mutation | c.604N>A | p.Glu202Lys | p.E202K | Q9UNN5 | protein_coding | tolerated(0.77) | benign(0.164) | TCGA-EX-A1H6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAF1 | SNV | Missense_Mutation | novel | c.1479A>T | p.Glu493Asp | p.E493D | Q9UNN5 | protein_coding | tolerated(0.57) | benign(0.072) | TCGA-MA-AA3Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FAF1 | insertion | Frame_Shift_Ins | novel | c.1597_1598insGA | p.Met533ArgfsTer26 | p.M533Rfs*26 | Q9UNN5 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| FAF1 | SNV | Missense_Mutation | novel | c.1647A>C | p.Glu549Asp | p.E549D | Q9UNN5 | protein_coding | tolerated(0.11) | possibly_damaging(0.679) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FAF1 | SNV | Missense_Mutation | c.1498N>A | p.Glu500Lys | p.E500K | Q9UNN5 | protein_coding | deleterious(0) | possibly_damaging(0.679) | TCGA-AD-6963-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| FAF1 | SNV | Missense_Mutation | c.1805T>G | p.Phe602Cys | p.F602C | Q9UNN5 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| FAF1 | SNV | Missense_Mutation | novel | c.571N>C | p.Asn191His | p.N191H | Q9UNN5 | protein_coding | tolerated(0.2) | possibly_damaging(0.453) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |